Updated:
Balchem
Balchem is a publicly traded NASDAQ compounder operating in human nutrition, animal health, and specialty gases with eight global innovation centers.
Balchem
Discover how Balchem is making the world a healthier place. Trusted, science-based solutions for nutrition, health & food markets.
General information
Firm type
Asset Manager
Year founded
1967
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, United States
Sector focus
Frequently asked questions
How is Balchem structured as an investment vehicle?
Balchem is a publicly traded operating company listed on the NASDAQ (BCPC), not a fund or family office. It deploys permanent public equity capital into bolt-on acquisitions that integrate into its three existing business segments. This structure gives it an indefinite holding period rather than a fixed fund life.
What are Balchem's core business segments?
The firm operates through Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The latter subdivides into Performance Gases (specialty gas packaging and distribution) and Plant Nutrition (Metalosate chelated minerals). The company's platform originated in choline production and encapsulation technology.
Does Balchem invest in external funds or only deploy directly?
Balchem does not operate as an allocator or fund-of-funds. All capital deployment takes the form of corporate acquisitions absorbed into existing operating segments, alongside internal R&D product development across its eight US and European innovation centers.
Who runs investment and capital allocation decisions at Balchem?
Strategic capital allocation is governed by Balchem's public-company board and executive leadership team. The firm does not name a standalone chief investment officer; deal activity is driven by operating-segment leaders and corporate development under standard public-company governance.
What is Balchem's known posture on bolt-on acquisitions?
Balchem pursues bolt-on acquisitions that can be integrated into its Human Nutrition, Animal Nutrition, or Specialty Products segments. The strategy targets businesses where its microencapsulation and chelation technologies can extend margin or market scope, using its corporate balance sheet rather than dedicated fund commitments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: